natgillin/translations-raw huggingface dataset:
Enkelt subkutan eller intravenøs injektion i en dosis på 0,5 mg meloxicam/kg legemsvægt (d.v.s.
Single subcutaneous or intravenous injection at a dose of 0.5 mg meloxicam/kg body weight (i.e.
Enkelt subkutan eller intravenøs injektion på 0,5 mg meloxicam/kg legemsvægt (d.v.s.
Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e.
Enkelt subkutan eller intravenøs injektion på 0,5 mg meloxicam/kg legemsvægt (d.v.s.
Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e.,
Enkelt subkutan eller intravenøs injektion på 0,5 mg meloxicam/kg legemsvægt (d.v.s.
Single subcutaneous or intravenous injection at a dose of 0.5 mg meloxicam/kg body weight (i.e.
Enkelt subkutan injektion på 0,5 mg meloxicam/kg legemsvægt (d.v.s.
Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e.
Enkelt- og flerdosisfarmakokinetik af secukinumab hos patienter med plaque psoriasis blev påvist i flere studier med intravenøse doser varierende fra 1 x 0,3 mg/kg til 3 x 10 mg/kg og med subkutane doser varierende fra 1 x 25 mg til flere doser på 300 mg.
The single and multiple dose pharmacokinetics of secukinumab in plaque psoriasis patients were determined in several studies with intravenous doses ranging from 1x 0.3 mg/kg to 3x 10 mg/kg and with subcutaneous doses ranging from 1x 25 mg to multiple doses of 300 mg.
Enkelt- substitutionen D168V reducerede ikke følsomheden over for boceprevir.
The D168V single substitution did not reduce sensitivity to boceprevir.
enkelt-arm studie: Q3 2021
single-arm
Enkelt-doser på op til 10 mg/kg er administreret intravenøst i et klinisk studie uden dosisbegrænsende toksicitet.
Single doses up to 10 mg/kg intravenously have been administered in a clinical study without dose-limiting toxicity.
Enkelt-dosis hætteglas, pakke med 1
Single dose vial, pack of 1
Enkelt-serie (5 dages dosering, 23 dages behandlingspause) og 3- og 6-cycli toksicitetsundersøgelser blev udført på rotter og hunde.
Single-cycle (5 day dosing, 23 days non-treatment), 3- and 6 cycle toxicity studies were conducted in rats and dogs.
Enkeltarmsstudier af ALK-positiv fremskreden NSCLC
Single-arm studies in ALK-positive advanced NSCLC
Enkeltcenter-pilotforsøg N med CR = 11
Single Centre Pilot Trial N with CR = 11
Enkeltcenterforsøg N=12
Single Centre Trial N=12
Enkeltdele af en flerstykspakning må ikke sælges separat
Component of a multipack, can’t be sold separately.
Enkeltdele af en flerstykspakning må ikke sælges separat.
Component of a multipack, can’t be sold separately
enkeltdoser
ingle dose
Enkeltdoser af antacida (magnesiumhydroxid/aluminiumhydroxid) påvirkede ikke biotilgængelig- heden af sildenafil.
Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil.
Enkeltdoser af raloxifen, som blev givet til patienter med cirrose og mild leverfunktionsnedsættelse (Child-Pugh klasse A), medførte plasmakoncen- trationer af raloxifen, som var 2,5 gange højere end hos kontrolgruppen.
Single doses of raloxifene given to patients with cirrhosis and mild hepatic impairment (Child-Pugh class A) produced plasma concentrations of raloxifene which were approximately 2.5 times the controls.
Enkeltdoser op til 1200 mg og gentagne doser op til 1200 mg 2 gange dagligt er blevet givet til raske personer i 9 dage uden klinisk betydende bivirkninger.
Single doses up to 1400 mg and multiple doses up to 1400 mg twice daily have been administered to healthy subjects for nine days without clinically significant adverse events.
Enkeltdoser over 25 mg/kg (1.727 mg) er ikke afprøvet i kliniske studier.
In clinical trials, single doses higher than 25 mg/kg (1727 mg) have not been tested.
Enkeltdoser på 10 mg og 80 mg vardenafil er vist at kunne forlænge QTc-intervallet med en middelværdi på henholdsvis 8 msek. og 10 msek.
Single oral doses of 10 mg and 80 mg of vardenafil have been shown to prolong the QTc interval by a mean of 8 msec and 10 msec, respectively.
Enkeltdoser på 10 mg vardenafil givet samtidig med 400 mg gatifloxacin, et aktivt stof med sammenlignelig QT-effekt, viste også en additiv QTc-effekt på 4 msek. i forhold til effekten ved hvert aktive stof for sig.
And single doses of 10 mg vardenafil co-administered concomitantly with 400 mg gatifloxacin, an active substance with comparable QT effect, showed an additive QTc effect of 4 msec when compared to either active substance alone.
Enkeltdoser på 10 mg vardenafil givet samtidig med 400 mg gatifloxacin, et aktivt stof med sammenlignelig QT-effekt, viste også en additiv QTc-effekt på 4 msek. i forhold til virkningen ved de aktive stoffer hver for sig.
And single doses of 10 mg vardenafil co-administered concomitantly with 400 mg gatifloxacin, an active substance with comparable QT effect, showed an additive QTc effect of 4 msec when compared to either active substance alone.
Enkeltdoser på op til 80 gange den anbefalede dosis (0,5 mg) tåltes godt af raske frivillige.
Single doses up to 80 times the recommended dose (0.5 mg) were well tolerated in healthy volunteers.
Enkeltdoserede multipakninger (perforeret enkeltdosisblister) indeholdende 98x1 tabletter (2 pakninger af 49x1).
Multi-packs of unit dose (perforated unit dose blister) containing 98x1 tablet (2 packs of 49x1)
Enkeltdoserede multipakninger (perforeret enkeltdosisblister) indeholdende 98x1 tabletter (2 pakninger af 49x1).
Multipacks of unit dose (perforated unit dose blister) containing 98x1 tablet (2 packs of 49x1)
enkeltdosi s
Single dose N=91
enkeltdosis
(mg)
enkeltdosis
500 mg single
enkeltdosis
avir
enkeltdosis
dose
enkeltdosis
Mechanism:
enkeltdosis
Single dose (N=140)
enkeltdosis
Single dose (N=86)
Enkeltdosis (ml)
Unit dose (ml)
enkeltdosis (n = 140)
Single dose (N=140)
enkeltdosis + Victrelis 800 mg 3
(sirolimus 2 mg single dose +
Enkeltdosis = 2 mg/50 mikroliter Ekstraherbar mængde = 4 mg/100 mikroliter
Single dose = 2 mg/50 microlitres Extractable content = 4 mg/100 microlitres
ENKELTDOSIS BLISTER (10 X 1 TABLETTER) FOR 2,5 MG
UNIT DOSE BLISTER (10 x 1 TABLETS) FOR 2.5 MG
Enkeltdosis fyldt sprøjte (0,5 ml)
Single-dose syringe (0.5ml)
Enkeltdosis hætteglas
Single-dose vial
Enkeltdosis injektionssprøjte (0,5 ml)
Single dose syringe (0.5ml)
enkeltdosis n = 51
Single dose N=51
enkeltdosis n = 91
Single dose N=91
ENKELTDOSIS PERFORERET BLISTER
UNIT DOSE PERFORATED BLISTER
enkeltdosis sildenafil på højst
benzodiazepine.
enkeltdosis tadalafil på højst 10 mg
especially if more than a single dose
enkeltdosis vardenafil på højst
Dose adjustment for
enkeltdosis én gang dagligt3
daily single dose3
enkeltdosis)
(100 mg single
enkeltdosis)
(50 mg single dose)
enkeltdosis)
single dose)
enkeltdosis)/cobicistat (150 mg
ingle dose)/cobicistat (150 mg multiple doses)
enkeltdosis)/elbasvir (50 mg en
0.15 mg LNG
enkeltdosis)/Elvitegravir (150 mg
single dose)/Elvitegravir (150 mg once daily)/Cobicistat (150 mg once daily)
enkeltdosis)/grazoprevir
0.15 mg LNG
enkeltdosis)/grazoprevir
single dose)/
enkeltdosis-
(glass) single dose vial
enkeltdosis-
yringe (glass) single dose vial
Enkeltdosis- blisterpakning
Perforated blister (PVC/Aclar/Alu)
Enkeltdosis- blisterpakning (PVC/Aclar/ aluminium)
Perforated blister (PVC/Aclar/Alu)
Enkeltdosis- farmakokinetik for aripiprazol var lineær og dosisproportionel.
The single- dose pharmacokinetics of aripiprazole was linear and dose-proportional.
Enkeltdosis-blisterpakninger i æsker med 100 x 1 filmovertrukne tabletter til hospitalsbrug kan også fås.
Unit dose blisters in cartons of 100 x 1 film-coated tablets for delivery in hospitals are also available.
Enkeltdosis-blisterpakninger i æsker med 60 x 1 og 100 x 1 filmovertrukne tabletter til hospitalsbrug kan også fås.
Unit dose blisters in cartons of 60 x 1 and 100 x 1 film-coated tablets for delivery in hospitals are also available.
Enkeltdosis-hætteglas
Single-dose vial
Enkeltdosis-injektionssprøjte
Single dose syringe
enkeltdosis-injektionssprøjter 4 enkeltdosis-injektionssprøjter 10 enkeltdosis-injektionssprøjter
single-dose syringes 4 single-dose syringes 10 single-dose syringes
enkeltdosis/600 mg én gang dagligt)
(250/100 mg single dose/600 mg once daily)
enkeltdosis/600 mg én gang dagligt)
tablets are coadministered.
Enkeltdosis: 0,3 mg/90 µl
Single dose: 0.3 mg/90 µl
Enkeltdosisbehold
Bottle (LDPE)
Enkeltdosisbehold
EU/1/02/205/006
ENKELTDOSISBEHOLDER
MONODOSE PRESENTATION
ENKELTDOSISBEHOLDER
SINGLE-DOSE CONTAINER
enkeltdosisbeholdere
Immediate
Enkeltdosisbeholderen skal ”knækkes” fri fra de andre (figur 1).
You will need to snap it apart where it joins the others (picture 1).
Enkeltdosisbeholderens spids må ikke berøre øjet, øjenlåget, det omgivende område eller andre overflader.
Don’t touch your eye or eyelid, surrounding areas or other surfaces with the container tip.
Enkeltdosisbeholderne skal anvendes senest 30 dage efter åbning af bakken.
Once the tray is opened, the single dose containers should be used within 30 days.
Enkeltdosisblister
Unit-dose blister
Enkeltdosisblister (30, 60, 90, 180 og 270)
Carton/Unit dose blisters (30, 60, 90, 180 and 270)
ENKELTDOSISBLISTER (PERFORERET) TEKST
UNIT DOSE BLISTER (PERFORATED) TEXT
enkeltdosisblister (PVC/PVDC/alu)
tablet (unit dose)
Enkeltdosisblisterne må ikke opbevares i køleskab eller nedfryses.
Do not refrigerate or freeze the unit dose blisters.
ENKELTDOSISBLISTERPAKNING (10×1 TABLETTER) FOR 20 MG
UNIT DOSE BLISTER (10 X 1 TABLETS) FOR 20 MG
Enkeltdosisblisterpakninger:
Unit Dose Blisters:
ENKELTDOSISBLISTRE
SINGLE-UNIT-DOSE BLISTERS
Enkeltdosisfarmakokinetik med rFVIIa, 15 og 30 µg pr. kg legemsvægt, udviste ingen signifikant forskel mellem de to doser med hensyn til dosisuafhængige parametre:
Single dose pharmacokinetics of rFVIIa, 15 and 30 μg per kg body weight, showed no significant difference between the two doses used with regard to dose-independent parameters:
Enkeltdosisfoliepose til ISENTRESS 100 mg granulat til oral suspension – foliepose
Unit dose sachet for ISENTRESS 100 mg granules for oral suspension – foil sachet
Enkeltdosispakning (perforeret enkeltdosisblister) indeholdende 56x1 tabletter.
Unit dose pack (perforated unit dose blister) containing 56x1 tablet
Enkelte dele må ikke sælges separat.
Component of a multipack, can’t be sold separately.
Enkelte doser på 1500 mg/kg (9000 mg/m2) og 720 mg/kg (14.400 mg/m2) tolereredes uden væsentlig toksicitet hos henholdsvis rotter og hunde.
Single doses of 1500 mg/kg (9000 mg/m2) and 720 mg/kg (14,400 mg/m2) were tolerated without significant toxicity in rats and dogs, respectively.
Enkelte doser på 80 mg/kg af den dispergible tablet-formulering af deferasirox (svarende til en dosis på 56 mg/kg af de filmovertrukne tabletter) i jernophobede, thalassæmipatienter forårsagede let kvalme og diarré.
Single doses of 80 mg/kg of the deferasirox dispersible tablet formulation (corresponding to a dose of 56 mg/kg film-coated tablets) in iron-overloaded thalassaemic patients caused mild nausea and diarrhoea.
Enkelte doser på 80 mg/kg af den dispergible tablet-formulering i jernophobede, thalassæmipatienter forårsagede let kvalme og diarré.
Single doses of 80 mg/kg of the deferasirox dispersible tablet formulation in iron-overloaded thalassaemic patients caused mild nausea and diarrhoea.
Enkelte doser på op til 20 mg/kg har væ ret indgivet uden toksiske virkninger.
Single doses up to 20 mg/kg have been administered without toxic effects.
Enkelte enheder fra en multipakning må ikke sælges seperat.
Component of a multipack, can’t be sold separately.
Enkelte inhalerede doser på op til 6.000 µg aclidiniumbromid er dog blevet administreret til raske forsøgspersoner uden systemiske antikolinerge bivirkninger.
However, single inhaled doses up to 6,000 µg aclidinium bromide have been administered to healthy subjects without systemic anticholinergic adverse effects.
Enkelte patienter kan udvikle faktor VIII-inhibitorer, dvs. antistoffer (proteiner), som kroppens immunsystem producerer mod faktor VIII, og som kan være årsag til, at lægemidlet holder op med at virke, hvilket medfører manglende kontrol med blødninger.
Some patients may develop factor VIII inhibitors, which are antibodies (proteins) that the body’s immune system produces against factor VIII and which can cause the medicine to stop working resulting in a loss of bleeding control.
Enkelte patienter kan udvise afvigende resultater for FVIII, idet de opnår andre værdier for in vivo-recovery og andre halveringstider.
Individual patients may vary in their response to FVIII, achieving different levels of in vivo recovery and demonstrating different half-lives.
Enkelte personer, som har haft hypoglykæmi efter at have skiftet fra animalsk insulin til human insulin har fortalt, at de tidlige advarselssymptomer for human insulin var mindre tydelige eller forskellige fra animalsk insulin.
A few people who have had hypoglycaemia after switching from animal insulin to human insulin have reported that the early warning symptoms were less obvious or different.
Enkeltinjektion
Single use injection.
Enkeltinstitutionsforsøget inkluderede 2 pædiatriske patienter (< 18 år gamle), som begge opnåede CR.
The single institution study included 2 paediatric patients (< 18 years old), both of whom achieved CR.
Enkeltpakninger indeholdende 28 hårde kapsler (7 dags blisterkort, hver indeholdende 4 hårde kapsler) eller 40 hårde kapsler (5 blisterkort, hver indeholdende 8 hårde kapsler).
Unit packs containing 28 hard capsules (7 daily blisters, each containing 4 hard capsules) or 40 hard capsules (5 blisters, each containing 8 hard capsules).
Enkeltpakninger indeholdende 28 hårde kapsler i en folder.
Unit packs containing 28 hard capsules in a wallet.
Enkeltpakninger med 6x1, 10x1, 12x1 og 30x1 kapsler og 1 inhalator.
Single pack containing 6x1, 10x1, 12x1 or 30x1 hard capsules, together with one inhaler.
Enkeltpakninger, der indeholder et brunligt hætteglas (glas) med gummiprop (chlorbutylgummi) med pulver til injektionsvæske, suspension og en farveløs fyldt injektionssprøjte (glas) med front- og stempelprop (chlorbutylgummi) med solvens, sampakket i en forseglet blisterbakke med en hætteglasadapter og en sikkerhedskanyle til injektion.
Unit packs containing one brownish vial (glass) with rubber stopper (chlorobutyl rubber) of powder for suspension for injection and one colourless pre-filled syringe (glass) with front and plunger stopper (chlorobutyl rubber) with solvent, co-packaged in a sealed blister tray with one vial adapter and one safety-engineered needle for injection.
Enkeltpersoner kan have større forhøjelser, end der afspejles i gennemsnitsændringerne.
Individuals may have larger increases than reflected by the mean changes.
Enkeltstofbehandling
Monotherapy:
Enkeltstofbehandling, placebokontrolleret studie
Monotherapy placebo-controlled study
Enkeltstående tilfælde af typiske NSAID-bivirkninger er observeret i kliniske undersøgelser (let nældefeber, diarré).
Isolated cases of adverse reactions typically associated with non-steroidal anti-inflammatory drugs (NSAIDs) were observed in clinical trials (slight urticaria, diarrhoea).
Enkeltstående typiske bivirkninger af NSAID’s (non-steroide antiinflammatoriske stoffer er observeret i kliniske undersøgelser (let nældefeber, diarré).
Isolated cases of adverse reactions typically associated with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) were observed in clinical trials (slight urticaria, diarrhoea).
enofovir
tricitabine/
enoxacin (et antibiotikum)
enoxacin (a type of antibiotic)
Enoxaparin blev evalueret hos 15.000 patienter, der fik enoxaparin i kliniske forsøg.
Enoxaparin was evaluated at 15,000 patients receiving enoxaparin in clinical trials.
Enoxaparin blev evalueret hos 15.000 patienter, der fik enoxaparin i kliniske studier.
Enoxaparin was evaluated at 15,000 patients receiving enoxaparin in clinical trials.
Enoxaparin er et lavmolekylært heparin med en gennemsnitlig molekylvægt på ca.
Enoxaparin is a low molecular weight heparin with a mean molecular weight of approximately
Enoxaparin i mindst 5 dage overlappet med og efterfulgt af VKA
Enoxaparin for at least 5 days, overlapped with and followed by VKA
Enoxaparin i mindst 5 dage, overlappende med og efterfulgt af VKA
Enoxaparin for at least 5 days, overlapped with and followed by VKA
Enoxaparin i mindst 5 dage, overlappet med og efterfulgt af VKA
Enoxaparin for at least 5 days, overlapped with and followed by VKA
Enoxaparin metaboliseres hovedsageligt i leveren, hvor det nedbrydes til molekyler med lav molekylvægt og signifikant reduceret biologisk aktivitet som resultat af spaltning af disulfidbinding (desulfation og depolymerisering).
Enoxaparin is metabolised mainly in the liver where it breaks down to molecules of lower molecular weight and significantly reduced biological activity as a result of disulphide bond cleavage (desulphation and depolymerisation).
Enoxaparin omsættes hovedsageligt i leveren, hvor det nedbrydes til molekyler af lav molekylvægt og signifikant reduceret biologisk aktivitet som resultat af spaltning af disulfidbinding (desulfation og depolymerisering).
Enoxaparin is metabolised mainly in the liver where it breaks down to molecules of lower molecular weight and significantly reduced biological activity as a result of disulphide bond cleavage (desulphation and depolymerisation).
Enoxaparin påvirker ikke evnen til at føre motorkøretøj eller betjene maskiner.
Enoxaparin has no effect on the ability to drive and operate machines.
Enoxaparin sammenlignet med ufraktioneret heparin reducerer signifikant recidivraten af koronar hjertesygdom, hjerteanfald og død.
Enoxaparin compared with unfractionated heparin significantly reduces the recurrence rate of coronary heart disease, heart attacks and death.
Enoxaparin var ikke mutagent i in vitro-test, inklusive Ames test, fremadmutationstest i muselymfomceller, kromosomaberrationstest i humane lymfocytter eller i in vivo kromosomaberrationstest i knoglemarv hos rotter.
Enoxaparin was not mutagenic in in vitro tests, including the Ames test, mouse lymphoma cell forward mutation test, and human lymphocyte chromosomal aberration test, and the in vivo rat bone marrow chromosomal aberration test.
Enoxaparin var ikke mutagent i in vitro-test, inklusive Ames test, test af fremadmutation i lymfomceller hos mus, test af kromosomafvigelse i humane lymfocytter samt in vivo-test af kromosomafvigelse i knoglemarv hos rotter.
Enoxaparin was not mutagenic in in vitro tests, including the Ames test, mouse lymphoma cell forward mutation test, and human lymphocyte chromosomal aberration test, and the in vivo rat bone marrow chromosomal aberration test.
Enoxaparin øger virkningen af antitrombin III, der er et naturligt stof, som kontrollerer blodstørkningsfaktorerne og medvirker til at forhindre blodet inde i kroppen i at størkne.
Enoxaparin increases the effect of antithrombin III, a natural substance that controls the blood’s clotting factors and helps prevent blood from clotting inside the body.
enoxaparin).
enoxaparin)
Enoxaparin/VKAb) 3, 6 eller 12 måneder
3, 6 or 12 months N=1,718
Enoxaparin/VKAb) 3, 6 eller 12 måneder
3, 6 or 12 months N=4,131
Enoxaparin/VKAb) 3, 6 eller 12 måneder
Enoxaparin/VKAb) 3, 6 or 12 months
Enoxaparin/warfari
Enoxaparin/Warfar
Enoxaparinnatriu
subcutan
Enoxaparinnatriu
ubcuta
Enoxaparinnatrium administreres som subkutan injektion til forebyggelse af venøs tromboemboli, til behandling af DVT, ustabil angina pectoris og non-Q-tak myokardieinfarkt samt til behandling af akut STEMI.
Enoxaparin sodium is administered by subcutaneous injection for the prevention of venous thromboembolism, for the treatment of DVT, for the treatment of unstable angina and non-Q-wave myocardial infarction and for the treatment of acute STEMI.
Enoxaparinnatrium bør anvendes med forsigtighed ved øget blødningsrisiko, f.eks.:
Enoxaparin sodium should be used with caution in situations of increased risk of bleeding, such as:
Enoxaparinnatrium bør til sådanne patienter ordineres i mindst 2 dage, og behandlingen bør fortsættes, til virkningen er opnået.
In these patients, enoxaparin sodium should be prescribed for at least 2 days and the treatment should be continued to achieve its objective.
Enoxaparinnatrium gives som injektion i arterieslangen i det ekstrakorporale kredsløb for at forebygge ekstrakorporal koageldannelse under hæmodialyse.
In order to prevent extracorporeal clot formation during haemodialysis, enoxaparin sodium is given by injection into the arterial line of the extracorporeal circulation.
Enoxaparinnatrium gives som injektion i arterieslangen i et ekstrakorporalt kredsløb for at forebygge ekstrakorporal koageldannelse under hæmodialyse.
In order to prevent extracorporeal clot formation during haemodialysis, enoxaparin sodium is given by injection into the arterial line of the extracorporeal circulation.
Enoxaparinnatrium skal anvendes med ekstrem forsigtighed hos patienter med trombocytopeni forårsaget af heparin, med eller uden trombose.
In patients with thrombocytopenia caused by the use of heparin, with or without thrombosis, enoxaparin sodium should be used with extreme caution.
Enoxaparinnatrium skal anvendes med ekstrem forsigtighed til patienter med trombocytopeni forårsaget af heparin, med eller uden trombose.
In patients with thrombocytopenia caused by the use of heparin, with or without thrombosis, enoxaparin sodium should be used with extreme caution.
Enoxaparinnatrium, der tages gennem munden, optages i ringe grad, og selv større doser vil normalt ikke give alvorlige problemer.
Enoxaparin sodium administered orally is poorly absorbed and even large doses should not lead to serious consequences.
Enoxaparins aktivitetsniveau ved steady state er som forventet ud fra farmakokinetikken for en enkelt dosis.
Steady-state enoxaparin activity levels are well predicted by single dose pharmacokinetics.
Enoxaparins aktivitetsniveau ved steady state er som foventet ud fra farmakokinetikken for en enkelt dosis.
Steady-state enoxaparin activity levels are well predicted by single dose pharmacokinetics.
Enoxaparins aktivitetsniveauer ved steady state er forudsigelige ud fra farmakokinetikken for en enkelt dosis.
Steady-state enoxaparin activity levels are well predicted by single dose pharmacokinetics.
Enoxaparins aktivitetsniveauer ved steady state er som forventet ud fra farmakokinetikken for en enkelt dosis.
Steady-state enoxaparin activity levels are well predicted by single dose pharmacokinetics.
Enoxaparins farmakokinetik er blevet undersøgt på grundlag af plasmaniveauer af anti-Xa- og anti-IIb-aktivitet ved de anbefalede doser efter enkelt og gentagen subkutan administration og efter en enkelt intravenøs injektion.
The pharmacokinetics of enoxaparin have been studied on the basis of plasma levels of anti-Xa activity and activity of anti-IIb at the recommended doses following single and repeated subcutaneous administration, and following single intravenous injection.
Enoxaparins farmakokinetik er blevet undersøgt på grundlag af plasmaniveauer af anti-Xa- og anti-IIb-aktivitet ved de anbefalede doser efter enkelt og gentagen subkutan administration og efter enkelt intravenøs injektion.
The pharmacokinetics of enoxaparin have been studied on the basis of plasma levels of anti-Xa activity and activity of anti-IIb at the recommended doses following single and repeated subcutaneous administration, and following single intravenous injection.
Enoxaparins farmakokinetik lader til at være lineær for de anbefalede dosisintervaller.
Enoxaparin pharmacokinetics appears to be linear over the recommended dose ranges.
Enoxaparins farmakokinetik synes at være lineær ved de anbefalede dosisintervaller.
Enoxaparin pharmacokinetics appears to be linear over the recommended dose ranges.
Enoxaparins farmakokinetik synes at være linær ved de anbefalede dosisintervaller.
Enoxaparin pharmacokinetics appears to be linear over the recommended dose ranges.